Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  GDC-0077

GDC-0077

Basic information Safety Supplier Related

GDC-0077 Basic information

Product Name:
GDC-0077
Synonyms:
  • GDC-0077
  • CPD1573
  • RG 6114
  • RO 7113755
  • GDC-0077; RG 6114; RO 7113755
  • (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
  • Propanamide, 2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]-, (2S)-
  • Inavolisib
CAS:
2060571-02-8
MF:
C18H19F2N5O4
MW:
407.37
Mol File:
2060571-02-8.mol
More
Less

GDC-0077 Chemical Properties

Boiling point:
698.0±65.0 °C(Predicted)
Density 
1.63±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO:110.0(Max Conc. mg/mL);245.47(Max Conc. mM)
pka
15.89±0.50(Predicted)
form 
Solid
color 
Off-white to yellow
InChIKey
SGEUNORSOZVTOL-CABZTGNLSA-N
SMILES
C(N)(=O)[C@@H](NC1C=C2OCCN3C=C(N4[C@H](C(F)F)COC4=O)N=C3C2=CC=1)C
More
Less

GDC-0077 Usage And Synthesis

Description

Inavolisib, or GDC-0077, is a potent and selective PI3K inhibitor. GDC-0077 blocks an enzyme involved in cancer growth called PI3K. GDC0077 binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and inhibits the growth and survival of PI3K-overexpressing tumor cells. The IUPAC name of this compound is (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide.

in vitro

GDC-0077 (RG6114) is >300-fold more selective for PI3Kα over the other class I PI3K isoforms (β, δ, and γ) and >2000-fold more selective over PIK family members. GDC-0077 selectively degrades mutant PI3Kα in a proteasome-dependent fashion, resulting in a reduction of PI3K pathway activity biomarkers such as pAKT and pPRAS40, inhibition of cell proliferation, and increased apoptosis in human PIK3CA-mutant breast cancer cell lines to a greater extent when compared to PIK3CA wild-type cells.

GDC-0077Supplier

Shanghai Tachizaki Biomedical Research Center Gold
Tel
18014399201
Email
sales@chemlab-tachizaki.com
Hubei Chuchang Chemical Co., Ltd Gold
Tel
15623560702
Email
Joy.Ren@aliyun.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com
Sichuan Wei Keqi Biological Technology Co., Ltd.
Tel
028-81700200 18116577057
Email
3003855609@qq.com
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266